R3 Stem Cell gets authorized access to MuseCells in Mexico

By AI, Created 11:03 AM UTC, May 20, 2026, /AGP/ – R3 Stem Cell International has been designated an authorized provider of Dezawa MuseCells® by MuseCell Innovations®, giving its Mexico clinics access to the licensed products under local regulatory rules. The move expands the company’s authorized regenerative therapy offerings in Tijuana, Puerto Vallarta and Cancun and comes with sourcing, training and quality requirements.

Why it matters: - The designation gives R3 Stem Cell International licensed access to a distinct cell and extracellular vesicle platform across its Mexico clinic network. - The authorization expands the company’s product portfolio while tying use of Dezawa MuseCells® and Dezawa MuseExosomes® to defined sourcing, training and quality standards. - The move matters for patients in Mexico because the products can be offered only in clinics operating under the applicable national regulatory framework.

What happened: - R3 Stem Cell International said MuseCell Innovations® designated the company an Authorized Provider of Dezawa MuseCells®, effective May 2026. - The authorization applies to all R3 Stem Cell International clinics in Mexico. - The Mexico locations covered include Tijuana, Puerto Vallarta and Cancun. - The agreement allows the clinics to deliver protocols incorporating MCI-licensed cell products under Mexican regulatory rules.

The details: - MuseCell Innovations® is the sole global licensor of the Dezawa MuseCell® and Dezawa MuseExosome® intellectual property developed by Professor Mari Dezawa and the Department of Stem Cell Biology and Histology at Tohoku University Graduate School of Medicine in Japan. - Muse cells were first reported in 2010 as a subpopulation of pluripotent-like stem cells characterized by SSEA-3 surface expression. - The release describes Muse cells in the literature as non-tumorigenic, immune-tolerant and capable of multilineage differentiation. - Under the agreement, R3 Stem Cell International can access Dezawa MuseCells® and Dezawa MuseExosomes® at all Mexico clinic locations in accordance with MCI sourcing and quality standards. - The company can use the registered marks under MCI marketing and trademark-use guidelines. - R3 Stem Cell International can participate in MCI clinician training and quality assurance programs. - The agreement also allows voluntary, de-identified contributions to multi-center clinical outcomes data initiatives where established by MCI and allowed by local ethical and regulatory requirements. - In Mexico, cell-based and extracellular vesicle products are regulated by COFEPRIS and applicable provisions of the General Health Law and its Regulations on Health Research. - R3 Stem Cell International said Dezawa MuseCells® and Dezawa MuseExosomes® are administered only in jurisdictions where the products are authorized under the applicable national regulatory framework. - The company says it has completed more than 28,000 stem cell procedures in the past decade and reports an 85% patient satisfaction rate worldwide. - R3 Stem Cell International operates clinics in Mexico, the UAE, Pakistan, India, Turkey, the Philippines, South Africa and the U.S. - The company says it operates approximately 80 affiliated clinics in eight countries. - The company says its clinics deliver cell-based and biologic protocols with stem cells, exosomes and PRP under locally licensed clinicians and applicable national regulators. - R3 Stem Cell International’s research team says it has published 12 peer-reviewed studies over the past three years. - The company pointed to a recent peer-reviewed study on intranasal stem cell administration published in Frontiers in Aging Neuroscience, available here. - Additional information about R3 Stem Cell International is available at the company website.

Between the lines: - The authorization gives R3 Stem Cell International a formal commercial pathway for using a branded cell product family in Mexico, which can be important in a field where sourcing and regulatory status often determine what clinics can offer. - The company is pairing the licensing announcement with a broader message about research, registry collection and publication, which suggests an effort to build both clinical and scientific credibility. - The release also includes a caution that the existing clinical evidence is preliminary in many indications and that controlled prospective studies are needed to establish efficacy.

What’s next: - R3 Stem Cell International said prospective observational registry protocols for selected indications are in development for review by CONBIOÉTICA-registered ethics committees in Mexico. - The company plans ClinicalTrials.gov registration before enrollment. - Outcomes from patients treated with Dezawa MuseCells® or Dezawa MuseExosomes® may be included in registries on a voluntary, informed-consent basis with independent oversight, pre-specified endpoints and a commitment to publish results regardless of outcome. - The company said the authorized-provider framework and local regulatory review will govern future use of the products in Mexico.

The bottom line: - R3 Stem Cell International has secured a formal license-backed route to offer Muse cell-related products in Mexico, but the company’s future claims about clinical value will depend on the registry data and prospective studies it says are coming.